Altimmune, Inc.
ALTHeld by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase2 readout (Pemvidutide): Sep 2027. Short interest: 23.7% of float.
Held by 7 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying7 funds opened new positions. Next phase2 readout (Pemvidutide): Sep 2027. Short interest: 23.7% of float.
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for obesity and various liver diseases. Its primary investigational drug, pemvidutide (proposed INN, previously known as ALT-801), operates as a GLP-1/glucagon dual receptor agonist. This compound is currently undergoing Phase 1b clinical trials, exploring its efficacy in treating both obesity and non-alcoholic steatohepatitis (NASH). Additionally, Altimmune is advancing HepTcell, an immunotherapeutic candidate, through Phase 2 clinical trials. This therapy is designed for individuals suffering from chronic hepatitis B virus infection. The enterprise, initially named Vaxin Inc., officially adopted the Altimmune, Inc. moniker in September 2015. Established in 1997, the company maintains its corporate headquarters in Gaithersburg, Maryland.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.